Sabra Health Care REIT Analyst Ratings
Sabra Health Care REIT Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/10/2023 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 10/03/2023 | 12.28% | Wedbush | → $16 | Initiates Coverage On | → Outperform |
| 09/20/2023 | 5.26% | Jefferies | $11 → $15 | Upgrades | Hold → Buy |
| 08/11/2023 | -1.75% | B of A Securities | $11 → $14 | Upgrades | Underperform → Neutral |
| 07/27/2023 | -8.77% | Berenberg | → $13 | Initiates Coverage On | → Hold |
| 07/14/2023 | -12.28% | Citigroup | $11 → $12.5 | Maintains | Neutral |
| 04/25/2023 | -8.77% | Barclays | $15 → $13 | Maintains | Equal-Weight |
| 04/20/2023 | -22.81% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
| 04/19/2023 | -22.81% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
| 04/12/2023 | -8.77% | Credit Suisse | → $13 | Reiterates | → Neutral |
| 03/29/2023 | -8.77% | Truist Securities | $14 → $13 | Maintains | Buy |
| 03/28/2023 | -26.32% | Citigroup | $13 → $10.5 | Maintains | Neutral |
| 12/13/2022 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 11/14/2022 | -8.77% | B of A Securities | $15 → $13 | Downgrades | Neutral → Underperform |
| 10/10/2022 | -8.77% | Baird | → $13 | Downgrades | Outperform → Neutral |
| 06/30/2022 | -1.75% | Jefferies | $15 → $14 | Downgrades | Buy → Hold |
| 05/25/2022 | 5.26% | Mizuho | $16 → $15 | Upgrades | Neutral → Buy |
| 04/18/2022 | -1.75% | Barclays | $16 → $14 | Downgrades | Overweight → Equal-Weight |
| 04/04/2022 | 5.26% | Credit Suisse | $14 → $15 | Maintains | Neutral |
| 03/11/2022 | 5.26% | B of A Securities | → $15 | Upgrades | Underperform → Neutral |
| 02/23/2022 | 26.32% | Stifel | $21 → $18 | Maintains | Buy |
| 02/18/2022 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 02/01/2022 | -1.75% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
| 09/30/2021 | 26.32% | Truist Securities | → $18 | Upgrades | Hold → Buy |
| 09/13/2021 | 40.35% | JMP Securities | $24 → $20 | Maintains | Market Outperform |
| 05/21/2021 | 47.37% | BMO Capital | $20 → $21 | Upgrades | Market Perform → Outperform |
| 05/10/2021 | 47.37% | Stifel | $17 → $21 | Upgrades | Hold → Buy |
| 01/13/2021 | 40.35% | Jefferies | $17 → $20 | Upgrades | Hold → Buy |
| 01/08/2021 | 33.33% | BMO Capital | → $19 | Upgrades | Underperform → Market Perform |
| 12/03/2020 | 68.42% | JMP Securities | → $24 | Upgrades | Market Perform → Market Outperform |
| 09/02/2020 | 5.26% | Stifel | → $15 | Reinstates | → Hold |
| 06/23/2020 | 5.26% | Scotiabank | $12 → $15 | Upgrades | Sector Underperform → Sector Perform |
| 06/22/2020 | -1.75% | Wells Fargo | $13 → $14 | Maintains | Equal-Weight |
| 05/18/2020 | 5.26% | Berenberg | → $15 | Upgrades | Hold → Buy |
| 04/23/2020 | — | SunTrust Robinson Humphrey | Maintains | Hold | |
| 04/07/2020 | -29.82% | Citigroup | $20 → $10 | Maintains | Neutral |
| 03/26/2020 | -26.32% | Wells Fargo | $22 → $10.5 | Maintains | Equal-Weight |
| 02/26/2020 | 54.39% | Mizuho | → $22 | Upgrades | Neutral → Buy |
| 02/06/2020 | 75.44% | Barclays | $26 → $25 | Maintains | Overweight |
| 02/05/2020 | 54.39% | Berenberg | → $22 | Initiates Coverage On | → Hold |
| 12/20/2019 | 54.39% | Mizuho | → $22 | Initiates Coverage On | → Neutral |
| 12/18/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
| 10/14/2019 | — | B of A Securities | Reinstates | → Neutral | |
| 09/27/2019 | 61.4% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
| 09/23/2019 | 40.35% | Citigroup | $18 → $20 | Downgrades | Neutral → Sell |
| 09/03/2019 | 68.42% | Barclays | → $24 | Initiates Coverage On | → Overweight |
| 02/26/2019 | — | BMO Capital | Downgrades | Market Perform → Underperform | |
| 12/17/2018 | 33.33% | Wells Fargo | $23 → $19 | Maintains | Market Perform |
| 11/16/2018 | 47.37% | B of A Securities | $23 → $21 | Downgrades | Neutral → Underperform |
| 11/16/2018 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 11/13/2018 | 47.37% | Mizuho | → $21 | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月10日 | - | B of A證券 | 升級 | 中性→購買 | |
| 10/03/2023 | 12.28% | 韋德布什 | →$16 | 開始承保 | →跑贏大盤 |
| 09/20/2023 | 5.26% | 傑富瑞 | $11→$15 | 升級 | 持有→購買 |
| 2023年08月11日 | -1.75% | B of A證券 | $11→$14 | 升級 | 表現不佳的→中性 |
| 07/27/2023 | -8.77% | 貝倫伯格 | →$13 | 開始承保 | →保留 |
| 07/14/2023 | -12.28% | 花旗集團 | $11→$12.5 | 維護 | 中性 |
| 04/25/2023 | -8.77% | 巴克萊 | $15→$13 | 維護 | 等重 |
| 04/20/2023 | -22.81% | 富國銀行 | →$11 | 開始承保 | →減持 |
| 04/19/2023 | -22.81% | 富國銀行 | →$11 | 開始承保 | →減持 |
| 04/12/2023 | -8.77% | 瑞士信貸 | →$13 | 重申 | →中性 |
| 03/29/2023 | -8.77% | Truist證券 | $14→$13 | 維護 | 買 |
| 03/28/2023 | -26.32% | 花旗集團 | $13→$10.5 | 維護 | 中性 |
| 2022年12月13日 | - | JMP證券 | 評級下調 | 市場表現優於→市場表現 | |
| 2022年11月14日 | -8.77% | B of A證券 | $15→$13 | 評級下調 | 中性→表現不佳 |
| 2022年10月10日 | -8.77% | 貝爾德 | →$13 | 評級下調 | 跑贏→中性 |
| 2022/06/30 | -1.75% | 傑富瑞 | $15→$14 | 評級下調 | 購買→Hold |
| 2022年05月25日 | 5.26% | 瑞穗 | $16→$15 | 升級 | 中性→購買 |
| 04/18/2022 | -1.75% | 巴克萊 | $16→$14 | 評級下調 | 超重→等重 |
| 04/04/2022 | 5.26% | 瑞士信貸 | $14→$15 | 維護 | 中性 |
| 03/11/2022 | 5.26% | B of A證券 | →$15 | 升級 | 表現不佳的→中性 |
| 02/23/2022 | 26.32% | Stifel | $21→$18 | 維護 | 買 |
| 02/18/2022 | - | KeyBanc | 開始承保 | →行業權重 | |
| 02/01/2022 | -1.75% | 瑞士信貸 | →$14 | 開始承保 | →中性 |
| 09/30/2021 | 26.32% | Truist證券 | →$18 | 升級 | 持有→購買 |
| 09/13/2021 | 40.35% | JMP證券 | $24→$20 | 維護 | 市場表現強於大盤 |
| 2021/05/21 | 47.37% | 蒙特利爾銀行資本 | $20→$21 | 升級 | 市場表現優於→ |
| 2021/05/10 | 47.37% | Stifel | $17→$21 | 升級 | 持有→購買 |
| 2021/01/13 | 40.35% | 傑富瑞 | $17→$20 | 升級 | 持有→購買 |
| 01/08/2021 | 33.33% | 蒙特利爾銀行資本 | →$19 | 升級 | 表現遜於→市場表現 |
| 12/03/2020 | 68.42% | JMP證券 | →$24 | 升級 | 市場表現優於→市場表現 |
| 09/02/2020 | 5.26% | Stifel | →$15 | 恢復 | →保留 |
| 2020/06/23 | 5.26% | 加拿大豐業銀行 | $12→$15 | 升級 | 行業表現遜於→行業表現 |
| 06/22/2020 | -1.75% | 富國銀行 | $13→$14 | 維護 | 等重 |
| 05/18/2020 | 5.26% | 貝倫伯格 | →$15 | 升級 | 持有→購買 |
| 04/23/2020 | - | SunTrust Robinson Humphrey | 維護 | 保持 | |
| 04/07/2020 | -29.82% | 花旗集團 | $20→$10 | 維護 | 中性 |
| 03/26/2020 | -26.32% | 富國銀行 | $22→$10.5 | 維護 | 等重 |
| 02/26/2020 | 54.39% | 瑞穗 | →$22 | 升級 | 中性→購買 |
| 02/06/2020 | 75.44% | 巴克萊 | $26→$25 | 維護 | 超重 |
| 02/05/2020 | 54.39% | 貝倫伯格 | →$22 | 開始承保 | →保留 |
| 2019年12月20日 | 54.39% | 瑞穗 | →$22 | 開始承保 | →中性 |
| 2019年12月18日 | - | 花旗集團 | 升級 | 賣出→中性 | |
| 2019年10月14日 | - | B of A證券 | 恢復 | →中性 | |
| 2019年09月27日 | 61.4% | JMP證券 | $22→$23 | 維護 | 市場表現強於大盤 |
| 2019年09月23日 | 40.35% | 花旗集團 | $18→$20 | 評級下調 | 中性→銷售 |
| 2019年09月03日 | 68.42% | 巴克萊 | →$24 | 開始承保 | →超重 |
| 2019年02月26日 | - | 蒙特利爾銀行資本 | 評級下調 | 市場表現→表現不佳 | |
| 2018年12月17日 | 33.33% | 富國銀行 | $23→$19 | 維護 | 市場表現 |
| 2018年11月16日 | 47.37% | B of A證券 | $23→$21 | 評級下調 | 中性→表現不佳 |
| 2018年11月16日 | - | 雷蒙德·詹姆斯 | 評級下調 | 跑贏→市場表現 | |
| 2018年11月13日 | 47.37% | 瑞穗 | →$21 | 評級下調 | 購買→中性 |
What is the target price for Sabra Health Care REIT (SBRA)?
Sabra Health Care REIT(SBRA)的目標價格是多少？
The latest price target for Sabra Health Care REIT (NASDAQ: SBRA) was reported by B of A Securities on October 10, 2023. The analyst firm set a price target for $0.00 expecting SBRA to fall to within 12 months (a possible -100.00% downside). 14 analyst firms have reported ratings in the last year.
美國銀行證券於2023年10月10日報告了Sabra Health Care REIT(納斯達克：SBRA)的最新目標價。這家分析公司將目標價定為0.00美元，預計SBRA將在12個月內下跌(可能下跌100.00%)。過去一年，有14家分析公司公佈了評級。
What is the most recent analyst rating for Sabra Health Care REIT (SBRA)?
Sabra Health Care REIT(SBRA)的最新分析師評級是多少？
The latest analyst rating for Sabra Health Care REIT (NASDAQ: SBRA) was provided by B of A Securities, and Sabra Health Care REIT upgraded their buy rating.
納斯達克(SequoiaCapital：SBRA)的最新分析師評級由美國銀行證券提供，Sabra Health Care REIT上調了買入評級。
When is the next analyst rating going to be posted or updated for Sabra Health Care REIT (SBRA)?
Sabra Health Care REIT(SBRA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sabra Health Care REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sabra Health Care REIT was filed on October 10, 2023 so you should expect the next rating to be made available sometime around October 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Sabra Health Care REIT的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Sabra Health Care REIT的上一次評級是在2023年10月10日提交的，因此您應該預計下一次評級將在2024年10月10日左右的某個時候提供。
Is the Analyst Rating Sabra Health Care REIT (SBRA) correct?
分析師對Sabra Health Care REIT(SBRA)的評級正確嗎？
While ratings are subjective and will change, the latest Sabra Health Care REIT (SBRA) rating was a upgraded with a price target of $0.00 to $0.00. The current price Sabra Health Care REIT (SBRA) is trading at is $14.25, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Sabra Health Care REIT(SBRA)評級被上調，目標價為0.00美元至0.00美元。Sabra Health Care REIT(SBRA)目前的交易價格為14.25美元，超出了分析師的預測區間。